Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer
Aim - to investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical outcome. The study was conducted within the...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2013 |
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2013
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/145215 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer / O.V. Skachkova, N.M. Khranovska, O.I. Gorbach, N.M. Svergun, R.I. Sydor, V.V. Nikulina // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 109-113. — Бібліогр.: 14 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
nasplib_isofts_kiev_ua-123456789-145215 |
|---|---|
| record_format |
dspace |
| spelling |
Skachkova, O.V. Khranovska, N.M. Gorbach, O.I. Svergun, N.M. Sydor, R.I. Nikulina, V.V. 2019-01-19T12:36:26Z 2019-01-19T12:36:26Z 2013 Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer / O.V. Skachkova, N.M. Khranovska, O.I. Gorbach, N.M. Svergun, R.I. Sydor, V.V. Nikulina // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 109-113. — Бібліогр.: 14 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/145215 Aim - to investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical outcome. The study was conducted within the framework of randomized phase III clinical trial of DC-vaccine efficacy in patients with non-small cell lung cancer. Quantitative composition of peripheral blood lymphocytes was determined by flow cytometry. Cytokines mRNA expression level was estimated using real-time RT-PCR. In our study the most pronounced changes in the immune system have been defined after fourth DC-vaccine injection. Immunologic features such as reduction the MIP-1 alpha mRNA expression level, increasing the RANTES mRNA expression level and NK-cells count, retention CD4/CD8 ratio at physiological level were associated with favorable clinical outcome after DC-immunotherapy. Conclusions: immunological markers established in our investigation can be used for estimation of DC-immunotherapy efficiency. The results of our research are very promising, but these data should be confirmed in further studies with a large cohort of patients. Key Words: lung cancer, DC-vaccine, immunological monitoring, effector cells, chemokines. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Original contributions Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer Article published earlier |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| title |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| spellingShingle |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer Skachkova, O.V. Khranovska, N.M. Gorbach, O.I. Svergun, N.M. Sydor, R.I. Nikulina, V.V. Original contributions |
| title_short |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| title_full |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| title_fullStr |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| title_full_unstemmed |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| title_sort |
immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer |
| author |
Skachkova, O.V. Khranovska, N.M. Gorbach, O.I. Svergun, N.M. Sydor, R.I. Nikulina, V.V. |
| author_facet |
Skachkova, O.V. Khranovska, N.M. Gorbach, O.I. Svergun, N.M. Sydor, R.I. Nikulina, V.V. |
| topic |
Original contributions |
| topic_facet |
Original contributions |
| publishDate |
2013 |
| language |
English |
| container_title |
Experimental Oncology |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| format |
Article |
| description |
Aim - to investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical outcome. The study was conducted within the framework of randomized phase III clinical trial of DC-vaccine efficacy in patients with non-small cell lung cancer. Quantitative composition of peripheral blood lymphocytes was determined by flow cytometry. Cytokines mRNA expression level was estimated using real-time RT-PCR. In our study the most pronounced changes in the immune system have been defined after fourth DC-vaccine injection. Immunologic features such as reduction the MIP-1 alpha mRNA expression level, increasing the RANTES mRNA expression level and NK-cells count, retention CD4/CD8 ratio at physiological level were associated with favorable clinical outcome after DC-immunotherapy. Conclusions: immunological markers established in our investigation can be used for estimation of DC-immunotherapy efficiency. The results of our research are very promising, but these data should be confirmed in further studies with a large cohort of patients. Key Words: lung cancer, DC-vaccine, immunological monitoring, effector cells, chemokines.
|
| issn |
1812-9269 |
| url |
https://nasplib.isofts.kiev.ua/handle/123456789/145215 |
| citation_txt |
Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer / O.V. Skachkova, N.M. Khranovska, O.I. Gorbach, N.M. Svergun, R.I. Sydor, V.V. Nikulina // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 109-113. — Бібліогр.: 14 назв. — англ. |
| work_keys_str_mv |
AT skachkovaov immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer AT khranovskanm immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer AT gorbachoi immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer AT svergunnm immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer AT sydorri immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer AT nikulinavv immunologicalmarkersofantitumordendriticcellsvaccineefficiencyinpatientswithnonsmallcelllungcancer |
| first_indexed |
2025-12-02T12:21:15Z |
| last_indexed |
2025-12-02T12:21:15Z |
| _version_ |
1850862468203544576 |